• Nenhum resultado encontrado

Rev. Bras. Psiquiatr. vol.34 suppl.2

N/A
N/A
Protected

Academic year: 2018

Share "Rev. Bras. Psiquiatr. vol.34 suppl.2"

Copied!
1
0
0

Texto

(1)

Rev Bras Psiquiatr. 2012;34(Suppl2):S119-S120

Official Journal of the Brazilian Psychiatric Association Volume 34 • Supplement 2 • October/2012

Psychiatry

Revista Brasileira de Psiquiatria

EDITORIAL

1516-4446 - ©2012 Elsevier Editora Ltda. All rights reserved. doi:10.1016/j.rbp.2012.08.001

The relevance of neuroscience research networks for

Brazilian Science

Close contact between active researchers of linked special-ties is one of the most productive assets of modern science. The research laboratory itself is a mechanism of collabora-tion, and it is only logical that psychiatrists should embrace wider forms of partnership within other disciplines as well. This is a fundamental step towards integrating psychiatry into applied neuroscience research.1 The proximity allows for opportunities for research, training and mentoring that also have the potential of retaining future scientists in mental health research.

Translational research programs have been on the spot-light in psychiatry. Very recently, a panel went as far as stat-ing that “for better treatments, better science is needed”.2 Getting psychiatrists to talk to their peers might well be the way to integrate new methodologies and clinical neurosci-ence research. This is an approach we have adopted in two of the National Institutes for Science and Technology funded by the Brazilian Government in 2009: the National Institutes for Translational Medicine and Molecular Medicine.3,4

More recently, the creation of the Núcleo de Apoio à

Pesquisa em Neurociência Aplicada (NAPNA-USP) is another

such effort from a group of prominent scientists from the State of São Paulo. Such institutional support to neurosci-ence research is welcome and central to the development of psychiatry as an applied neuroscience discipline. NAPNA comprises 22 academic departments and laboratories that

are pursuing predeined aims in an orchestrated fashion. One

prominent target of NAPNA has been the investigation of the cannabinoid system. In this sense, new compounds have been developed and tested under the umbrella provided by NAPNA.5

In this vein, the articles in this issue represent an interest-ing sample of what this group is capable of producinterest-ing. It is a pleasure to see a supplement of RBP Psychiatry with such a carefully considered selection.

Flávio Kapczinski,

1

Marco Aurélio Romano-Silva

2

1 National Institute for Translational Medicine (INTM) 2 Pharmacology Department, Universidade Federal de Minas Gerais

Disclosures

Flávio Kapczinski

Employment: Instituto Nacional de Ciência e Tecnologia (National Institute for Science and Technology - INCT) Translational Medicine, Brazil.

Marco Aurélio Romano-Silva

Employment: Pharmacology Department, Universidade Federal de Minas Gerais, Brazil.

References

1. Reynolds CF, 3rd, Lewis DA, Detre T, Schatzberg AF, Kupfer DJ. The future of psychiatry as clinical neuroscience. Acad Med. 2009;84(4):446-50.

2. Insel TR, Sahakian BJ. Drug research: a plan for mental illness. Nature. 2012;483(7389):269.

3. Kapczinski F, Hallak JE, Nardi AE, Roesler R, Quevedo J, Schroder N, Crippa JAS. Brazil launches an innovative program to develop the National Institutes for Science and Technology (INCTs): the INCT for Translational Medicine. Rev Bras Psiquiatr. 2009;31(3):197-9.

4. Hallak JE, Crippa JA, Quevedo J, Roesler R, Schroder N, Nardi AE, Kapczinski F. National Science and Technology Institute for Translational Medicine (INCT-TM): advancing the ield of translational medicine and mental health. Rev Bras Psiquiatr. 2010;32(1):83-90.

Referências

Documentos relacionados

Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in

difference between patients and healthy volunteers (effect size g = 0.663, 95%CI = 0.365 to 0.961, p < 0.001), show- ing that patients under antipsychotic drug treatment have

27 evaluated the density of CB1-R in another area of the dlPFC (area 46) with the same ligand and found an increase in the density of this receptor in patients with

Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine- induced nigrostriatal terminal lesion model of Parkinson’s disease in the rat. Brain

Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy

factors for suicide include: presence of mood disorders (depression and bipolar disorder) and other psychiatric disorders (for example schizophrenia-like psychosis),

Laboratory of Panic and Respiration, Institute of Psychiatry, Universidade Federal do Rio de Janeiro (UFRJ); National Institute for Translational Medicine (INCT-TM), Brazil.

Employment: Universidade Federal do Extremo Sul Catarinense (UNESC); National Institute for Translational Medicine (INCT-TM), Brazil. Research Grant: Conselho Nacional